Pharma is hopeful about Trump's second term — here's what to expect for drugmakers

Pharmaceutical companies are optimistic about growth under the Trump administration, with hopes for a pro-business approach focusing on cracking down on pharmacy benefit managers and promoting drug innovation. Executives at the JPMorgan Health Care Conference expressed readiness to work with Trump, despite uncertainties around his administration, such as concerns about the anti-vaccine views of Robert F. Kennedy Jr., Trump’s pick for the Department of Health and Human Services. Overall, the industry is prepared to engage with the new administration and navigate potential challenges in the coming years.

Full Article